Immucell (ICCC) Current Deferred Tax Assets (2011 - 2015)

Immucell's (ICCC) quarterly Current Deferred Tax Assets came in at $69011.0 in Q3 2015, up 25.28% on a QoQ basis from $55087.0 in Q2 2015.

Immucell (ICCC) Current Deferred Tax Assets (2011 - 2015) Analysis & Trends

Immucell (ICCC) has 5 years of Current Deferred Tax Assets data on file, last reported at $69011.0 in Q3 2015.

Quarterly Current Deferred Tax Assets changed N/A year-over-year to $69011.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $69011.0 (changed N/A YoY) and the FY2014 annual result came in at $30463.0, up 100.26% from the prior year.
Current Deferred Tax Assets improved to $69011.0 in Q3 2015, from $55087.0 in the prior quarter.
In the past five years, Current Deferred Tax Assets ranged from a high of $69011.0 in Q3 2015 to a low of $3063.0 in Q1 2013.
A 5-year average of $29634.6 and a median of $24906.5 in 2013 frame the typical range for Current Deferred Tax Assets.
Annual changes were most pronounced in 2013 — Current Deferred Tax Assets plunged 91.68% — and 2014, when it jumped 225.69%.
Tracing ICCC's Current Deferred Tax Assets over 5 years: stood at $59016.0 in 2011, then sank by 47.17% to $31177.0 in 2012, then plunged by 51.21% to $15212.0 in 2013, then jumped by 100.26% to $30463.0 in 2014, then jumped by 126.54% to $69011.0 in 2015.
The last three Current Deferred Tax Assets figures came in at $69011.0 (Q3 2015), $55087.0 (Q2 2015), and $17673.0 (Q1 2015), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Immucell	91.19 Mn	82.33 Mn	2.44 Mn

Download Data